PL3023106T3 - Kompozycja antygenów mykobakteryjnych - Google Patents

Kompozycja antygenów mykobakteryjnych

Info

Publication number: PL3023106T3
Authority: PL; Poland
Prior art keywords: antigenic composition; mycobacterium; mycobacterium antigenic; composition; antigenic
Prior art date: 2010-12-14

Application number

PL15201196T

Other languages

English (en)

Inventor

Stephane Andre Georges Godart

Amina Laanan

Dominique Ingrid Lemoine

Original Assignee

Glaxosmithkline Biologicals S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-14

Filing date

2011-12-14

Publication date

2019-12-31

2011-12-14 Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.

2019-12-31 Publication of PL3023106T3 publication Critical patent/PL3023106T3/pl

Links

241000186359 Mycobacterium Species 0.000 title 1
230000000890 antigenic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pulmonology (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

PL15201196T 2010-12-14 2011-12-14 Kompozycja antygenów mykobakteryjnych PL3023106T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US42272310P	2010-12-14	2010-12-14
EP15201196.1A EP3023106B1 (en)	2010-12-14	2011-12-14	Mycobacterium antigenic composition
PCT/EP2011/072816 WO2012080369A1 (en)	2010-12-14	2011-12-14	Mycobacterium antigenic composition
EP11799673.6A EP2651437B1 (en)	2010-12-14	2011-12-14	Mycobacterium antigenic composition

Publications (1)

Publication Number	Publication Date
PL3023106T3 true PL3023106T3 (pl)	2019-12-31

Family

ID=45346501

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL11799673T PL2651437T3 (pl)	2010-12-14	2011-12-14	Kompozycja antygenów mykobakteryjnych
PL11794778.8T PL2651436T3 (pl)	2010-12-14	2011-12-14	Kompozycja antygenów mykobakteryjnych
PL15201196T PL3023106T3 (pl)	2010-12-14	2011-12-14	Kompozycja antygenów mykobakteryjnych

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL11799673T PL2651437T3 (pl)	2010-12-14	2011-12-14	Kompozycja antygenów mykobakteryjnych
PL11794778.8T PL2651436T3 (pl)	2010-12-14	2011-12-14	Kompozycja antygenów mykobakteryjnych

Country Status (33)

Country	Link
US (5)	US9730992B2 (pl)
EP (4)	EP3593813A1 (pl)
JP (2)	JP5951633B2 (pl)
KR (3)	KR101951894B1 (pl)
CN (4)	CN106822883A (pl)
AR (1)	AR084285A1 (pl)
AU (2)	AU2011343367B2 (pl)
BR (2)	BR112013014598A2 (pl)
CA (2)	CA2819297A1 (pl)
CO (2)	CO6751288A2 (pl)
CY (1)	CY1122187T1 (pl)
DK (3)	DK2651436T3 (pl)
EA (2)	EA027920B1 (pl)
ES (3)	ES2748651T3 (pl)
HR (3)	HRP20160362T1 (pl)
HU (3)	HUE027932T2 (pl)
IL (2)	IL226450A0 (pl)
LT (1)	LT3023106T (pl)
ME (1)	ME02380B (pl)
MX (2)	MX344706B (pl)
MY (1)	MY161412A (pl)
PH (2)	PH12013501204A1 (pl)
PL (3)	PL2651437T3 (pl)
PT (2)	PT2651436E (pl)
RS (1)	RS54687B1 (pl)
SG (2)	SG190937A1 (pl)
SI (3)	SI2651437T1 (pl)
SM (1)	SMT201600118B (pl)
TW (1)	TW201305192A (pl)
UA (2)	UA110118C2 (pl)
UY (1)	UY33802A (pl)
WO (2)	WO2012080370A1 (pl)
ZA (2)	ZA201304015B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2457926T3 (da)	2005-04-29	2015-01-05	Glaxosmithkline Biolog Sa	Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
CN106822883A (zh) *	2010-12-14	2017-06-13	葛兰素史密丝克莱恩生物有限公司	分枝杆菌抗原组合物
PL2661253T3 (pl) *	2011-01-04	2017-08-31	Archivel Farma, Sl	Preparat liposomowy odpowiedni do leczenia lub zapobiegania gruźlicy
DK2802345T3 (en)	2012-01-12	2018-04-30	Archivel Farma Sl	MTB-C-VACCINE AGAINST ALLERGIC REACTIONS
US9993427B2 (en)	2013-03-14	2018-06-12	Biorest Ltd.	Liposome formulation and manufacture
GB201405921D0 (en) *	2014-04-02	2014-05-14	Glaxosmithkline Biolog Sa	Novel methods for inducing an immune response
CA2946312A1 (en)	2014-04-23	2015-10-29	Juno Therapeutics, Inc.	Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
GB201513176D0 (en)	2015-07-27	2015-09-09	Glaxosmithkline Biolog Sa	Novel methods for inducing an immune response
GB201522068D0 (en) *	2015-12-15	2016-01-27	Glaxosmithkline Biolog Sa	Dried composition
US10695424B2 (en)	2016-12-07	2020-06-30	Glaxosmithkline Biologicals S.A.	Method of making a liposome composition
GB201621686D0 (en)	2016-12-20	2017-02-01	Glaxosmithkline Biologicals Sa	Novel methods for inducing an immune response
GB201707700D0 (en) *	2017-05-12	2017-06-28	Glaxosmithkline Biologicals Sa	Dried composition
GB2600653B (en)	2017-05-30	2022-11-02	Glaxosmithkline Biologicals Sa	Novel methods
BR112020010790A2 (pt)	2017-12-01	2020-11-10	Glaxosmithkline Biologicals S.A.	purificação da saponina
RU2728976C2 (ru) *	2018-03-22	2020-08-03	Зули Холдингз, Лтд.	Липосомный состав и его получение
CN112566654A (zh)	2018-07-31	2021-03-26	葛兰素史密丝克莱恩生物有限公司	抗原纯化方法
EP3886901A1 (en)	2018-11-29	2021-10-06	GlaxoSmithKline Biologicals S.A.	Methods for manufacturing an adjuvant
WO2020245207A1 (en)	2019-06-05	2020-12-10	Glaxosmithkline Biologicals Sa	Saponin purification
EP3777884A1 (en)	2019-08-15	2021-02-17	GlaxoSmithKline Biologicals S.A.	Immunogenic composition
WO2021048081A1 (en)	2019-09-09	2021-03-18	Glaxosmithkline Biologicals Sa	Immunotherapeutic compositions
US12533418B2 (en)	2019-11-22	2026-01-27	Glaxosmithkline Biologicals Sa	Dosage and administration of a bacterial saccharide glycoconjugate vaccine
EP4146378A1 (en)	2020-05-05	2023-03-15	GlaxoSmithKline Biologicals S.A.	Microfluidic mixing device and methods of use
WO2021245611A1 (en)	2020-06-05	2021-12-09	Glaxosmithkline Biologicals Sa	Modified betacoronavirus spike proteins
JP2023553904A (ja)	2020-12-09	2023-12-26	グラクソスミスクラインバイオロジカルズソシエテアノニム	サポニン
CN114034860A (zh) *	2021-11-01	2022-02-11	宁夏大学	一种结核分枝杆菌mtb39a蛋白抗体间接elisa检测方法及其试剂盒
JP2025525334A (ja)	2022-06-15	2025-08-05	グラクソスミスクラインバイオロジカルズソシエテアノニム	サポニンの酵素的修飾
CN116120411B (zh) *	2022-12-07	2024-04-12	中国疾病预防控制中心传染病预防控制所	结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4436727A (en)	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
US4866034A (en)	1982-05-26	1989-09-12	Ribi Immunochem Research Inc.	Refined detoxified endotoxin
US4877611A (en)	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
CA1331443C (en)	1987-05-29	1994-08-16	Charlotte A. Kensil	Saponin adjuvant
US5278302A (en)	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
ATE115862T1 (de)	1989-02-04	1995-01-15	Akzo Nobel Nv	Tocole als impfstoffadjuvans.
US5776468A (en)	1993-03-23	1998-07-07	Smithkline Beecham Biologicals (S.A.)	Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
EP1167379A3 (en)	1994-07-15	2004-09-08	University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2230927A1 (en)	1995-09-01	1997-03-13	Corixa Corporation	Compounds and methods for diagnosis of tuberculosis
AU727602B2 (en)	1995-09-01	2000-12-14	Corixa Corporation	Compounds and methods for immunotherapy and diagnosis of tuberculosis
US5666153A (en)	1995-10-03	1997-09-09	Virtual Shopping, Inc.	Retractable teleconferencing apparatus
GB9619613D0 (en)	1996-09-19	1996-10-30	Breed Automotive Tech	An inflatable restraint for a vehicle
EP0859366A1 (en)	1997-02-12	1998-08-19	STMicroelectronics S.r.l.	Associative memory device with optimized occupation, particularly for the recognition of words
PT973546E (pt) *	1997-04-08	2004-06-30	Merck & Co Inc	Formulacoes estabilizadas de virus de papiloma humano
US6303347B1 (en)	1997-05-08	2001-10-16	Corixa Corporation	Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en)	1997-05-08	2000-09-05	Ribi Immunochem Research, Inc.	Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en)	1997-05-08	2004-07-20	Corixa Corporation	Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en)	1997-12-24	1998-02-25	Smithkline Beecham Biolog	Vaccine
DE19803453A1 (de) *	1998-01-30	1999-08-12	Boehringer Ingelheim Int	Vakzine
PL202844B1 (pl) *	1998-04-07	2009-07-31	Corixa Corp	Immunogeniczny polipeptyd, polinukleotyd, polipeptyd, kompozycja farmaceutyczna, wektor ekspresji, kompozycja szczepionki, polipeptyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis, polinukleotyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis i sposób wytwarzania polipeptydu
WO1999052549A1 (en) *	1998-04-09	1999-10-21	Smithkline Beecham Biologicals S.A.	Adjuvant compositions
US7083796B2 (en) *	2000-06-20	2006-08-01	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis
US20040006242A1 (en)	1999-02-01	2004-01-08	Hawkins Lynn D.	Immunomodulatory compounds and method of use thereof
US6551600B2 (en)	1999-02-01	2003-04-22	Eisai Co., Ltd.	Immunological adjuvant compounds compositions and methods of use thereof
EP1229931A4 (en) *	1999-10-07	2003-05-28	Corixa Corp	FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
CZ20024224A3 (cs)	2000-06-29	2003-05-14	Glaxosmithkline Biologicals S. A.	Farmaceutický prostředek
US7026465B2 (en)	2002-02-15	2006-04-11	Corixa Corporation	Fusion proteins of Mycobacterium tuberculosis
GB0411411D0 (en)	2004-05-21	2004-06-23	Glaxosmithkline Biolog Sa	Vaccines
DK2457926T3 (da) *	2005-04-29	2015-01-05	Glaxosmithkline Biolog Sa	Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
US9297803B2 (en)	2006-11-01	2016-03-29	Immport Therapeutics, Inc.	Compositions and methods for immunodominant antigens
JP5331105B2 (ja)	2007-05-24	2013-10-30	グラクソスミスクラインバイオロジカルズソシエテアノニム	凍結乾燥抗原組成物
US8420081B2 (en)	2007-11-30	2013-04-16	Abbvie, Inc.	Antibody formulations and methods of making same
KR100955470B1 (ko) *	2008-01-09	2010-04-30	대한민국(관리부서 질병관리본부장)	탄저 방어 항원의 제조 방법
WO2009111874A1 (en)	2008-03-11	2009-09-17	The Royal Institution For The Advancement Of Learning/ Mcgiil University	Low-temperature wafer level processing for mems devices
GB0910046D0 (en) *	2009-06-10	2009-07-22	Glaxosmithkline Biolog Sa	Novel compositions
GB0910045D0 (en) *	2009-06-10	2009-07-22	Glaxosmithkline Biolog Sa	Novel compositions
GB201008512D0 (en)	2010-05-21	2010-07-07	Health Prot Agency	Mycobacterial antigen composition
IT1400834B1 (it)	2010-07-07	2013-07-02	Aero Sekur S P A	Metodo e sistema per l'atterraggio di emergenza di un veicolo, come un elicottero o simili.
CN106822883A (zh)	2010-12-14	2017-06-13	葛兰素史密丝克莱恩生物有限公司	分枝杆菌抗原组合物
GB201400819D0 (en)	2014-01-17	2014-03-05	Sec Dep For Health The	Mycobacterial antigen composition

2011
- 2011-12-14 CN CN201710066847.3A patent/CN106822883A/zh active Pending
- 2011-12-14 TW TW100146325A patent/TW201305192A/zh unknown
- 2011-12-14 CN CN201180060222.7A patent/CN103249431B/zh not_active Expired - Fee Related
- 2011-12-14 JP JP2013543775A patent/JP5951633B2/ja not_active Expired - Fee Related
- 2011-12-14 MX MX2013006818A patent/MX344706B/es active IP Right Grant
- 2011-12-14 DK DK11794778.8T patent/DK2651436T3/da active
- 2011-12-14 EA EA201390631A patent/EA027920B1/ru not_active IP Right Cessation
- 2011-12-14 CN CN201610883668.4A patent/CN106822882A/zh active Pending
- 2011-12-14 DK DK11799673.6T patent/DK2651437T3/en active
- 2011-12-14 KR KR1020137018060A patent/KR101951894B1/ko not_active Expired - Fee Related
- 2011-12-14 ME MEP-2016-60A patent/ME02380B/me unknown
- 2011-12-14 CA CA2819297A patent/CA2819297A1/en not_active Abandoned
- 2011-12-14 HU HUE11799673A patent/HUE027932T2/en unknown
- 2011-12-14 PL PL11799673T patent/PL2651437T3/pl unknown
- 2011-12-14 AR ARP110104678A patent/AR084285A1/es unknown
- 2011-12-14 ES ES15201196T patent/ES2748651T3/es active Active
- 2011-12-14 DK DK15201196.1T patent/DK3023106T3/da active
- 2011-12-14 BR BR112013014598A patent/BR112013014598A2/pt not_active Application Discontinuation
- 2011-12-14 US US13/993,386 patent/US9730992B2/en active Active
- 2011-12-14 MX MX2013006819A patent/MX344280B/es active IP Right Grant
- 2011-12-14 SI SI201130787A patent/SI2651437T1/sl unknown
- 2011-12-14 EP EP19188906.2A patent/EP3593813A1/en not_active Withdrawn
- 2011-12-14 KR KR1020197004934A patent/KR20190022897A/ko not_active Ceased
- 2011-12-14 HU HUE15201196A patent/HUE045766T2/hu unknown
- 2011-12-14 JP JP2013543776A patent/JP5951634B2/ja not_active Expired - Fee Related
- 2011-12-14 PL PL11794778.8T patent/PL2651436T3/pl unknown
- 2011-12-14 LT LT15201196T patent/LT3023106T/lt unknown
- 2011-12-14 PT PT117947788T patent/PT2651436E/pt unknown
- 2011-12-14 WO PCT/EP2011/072817 patent/WO2012080370A1/en not_active Ceased
- 2011-12-14 ES ES11794778.8T patent/ES2574403T3/es active Active
- 2011-12-14 AU AU2011343367A patent/AU2011343367B2/en not_active Ceased
- 2011-12-14 UY UY0001033802A patent/UY33802A/es not_active Application Discontinuation
- 2011-12-14 CN CN201180060489.6A patent/CN103260642B/zh not_active Expired - Fee Related
- 2011-12-14 AU AU2011343368A patent/AU2011343368C1/en not_active Ceased
- 2011-12-14 EP EP15201196.1A patent/EP3023106B1/en active Active
- 2011-12-14 UA UAA201306355A patent/UA110118C2/uk unknown
- 2011-12-14 MY MYPI2013700989A patent/MY161412A/en unknown
- 2011-12-14 WO PCT/EP2011/072816 patent/WO2012080369A1/en not_active Ceased
- 2011-12-14 CA CA2819298A patent/CA2819298A1/en not_active Abandoned
- 2011-12-14 PL PL15201196T patent/PL3023106T3/pl unknown
- 2011-12-14 EP EP11794778.8A patent/EP2651436B1/en active Active
- 2011-12-14 PH PH1/2013/501204A patent/PH12013501204A1/en unknown
- 2011-12-14 EP EP11799673.6A patent/EP2651437B1/en active Active
- 2011-12-14 SG SG2013041918A patent/SG190937A1/en unknown
- 2011-12-14 RS RS20160225A patent/RS54687B1/sr unknown
- 2011-12-14 HR HRP20160362TT patent/HRP20160362T1/hr unknown
- 2011-12-14 HU HUE11794778A patent/HUE028452T2/en unknown
- 2011-12-14 HR HRP20160606TT patent/HRP20160606T1/hr unknown
- 2011-12-14 KR KR1020137018059A patent/KR20140029376A/ko not_active Withdrawn
- 2011-12-14 BR BR112013014599A patent/BR112013014599A2/pt not_active Application Discontinuation
- 2011-12-14 PH PH1/2013/501203A patent/PH12013501203A1/en unknown
- 2011-12-14 US US13/993,736 patent/US9352030B2/en active Active
- 2011-12-14 SI SI201131805T patent/SI3023106T1/sl unknown
- 2011-12-14 SG SG2013041793A patent/SG190731A1/en unknown
- 2011-12-14 ES ES11799673.6T patent/ES2567190T3/es active Active
- 2011-12-14 SI SI201130859A patent/SI2651436T1/sl unknown
- 2011-12-14 EA EA201390630A patent/EA027504B1/ru not_active IP Right Cessation
- 2011-12-14 UA UAA201306356A patent/UA110806C2/uk unknown
- 2011-12-14 PT PT152011961T patent/PT3023106T/pt unknown
2013
- 2013-05-20 IL IL226450A patent/IL226450A0/en unknown
- 2013-05-20 IL IL226448A patent/IL226448A/en active IP Right Grant
- 2013-05-31 ZA ZA2013/04015A patent/ZA201304015B/en unknown
- 2013-05-31 ZA ZA2013/04014A patent/ZA201304014B/en unknown
- 2013-06-19 CO CO13146307A patent/CO6751288A2/es unknown
- 2013-06-19 CO CO13146289A patent/CO6751287A2/es unknown
2016
- 2016-04-18 US US15/131,422 patent/US20160220656A1/en not_active Abandoned
- 2016-04-22 SM SM201600118T patent/SMT201600118B/it unknown
2017
- 2017-07-06 US US15/643,084 patent/US10441648B2/en active Active
2019
- 2019-02-08 US US16/270,887 patent/US20190183998A1/en not_active Abandoned
- 2019-10-11 HR HRP20191843TT patent/HRP20191843T1/hr unknown
- 2019-10-18 CY CY20191101093T patent/CY1122187T1/el unknown

Also Published As

Publication number	Publication date
EA027504B1 (ru)	2017-08-31
AU2011343368A1 (en)	2013-07-11
EP2651437B1 (en)	2016-02-10
ES2748651T3 (es)	2020-03-17
CY1122187T1 (el)	2020-11-25
DK3023106T3 (da)	2019-09-30
CA2819298A1 (en)	2012-06-21
PH12013501203A1 (en)	2013-07-29
EA201390631A1 (ru)	2014-11-28
HUE027932T2 (en)	2016-11-28
DK2651437T3 (en)	2016-05-02
AU2011343367B2 (en)	2015-05-21
JP2013545783A (ja)	2013-12-26
EP3593813A1 (en)	2020-01-15
IL226448A0 (en)	2013-07-31
MX2013006818A (es)	2013-08-26
JP5951634B2 (ja)	2016-07-13
EA027920B1 (ru)	2017-09-29
PH12013501204A1 (en)	2013-07-29
JP2014505036A (ja)	2014-02-27
UY33802A (es)	2012-07-31
JP5951633B2 (ja)	2016-07-13
KR20130124525A (ko)	2013-11-14
PT2651436E (pt)	2016-06-08
KR20140029376A (ko)	2014-03-10
PT3023106T (pt)	2019-11-04
MX2013006819A (es)	2013-08-26
US9730992B2 (en)	2017-08-15
KR20190022897A (ko)	2019-03-06
MX344280B (es)	2016-12-09
AR084285A1 (es)	2013-05-08
CN106822882A (zh)	2017-06-13
WO2012080369A1 (en)	2012-06-21
AU2011343367A1 (en)	2013-07-11
PL2651436T3 (pl)	2016-10-31
SMT201600118B (it)	2016-07-01
US20160220656A1 (en)	2016-08-04
ES2567190T3 (es)	2016-04-20
WO2012080370A1 (en)	2012-06-21
UA110118C2 (uk)	2015-11-25
LT3023106T (lt)	2019-10-25
US20130280289A1 (en)	2013-10-24
RS54687B1 (sr)	2016-08-31
EP2651436B1 (en)	2016-03-30
AU2011343368C1 (en)	2015-12-24
CO6751288A2 (es)	2013-09-16
HRP20160362T1 (hr)	2016-05-06
HUE045766T2 (hu)	2020-01-28
CN103249431A (zh)	2013-08-14
US20180071378A1 (en)	2018-03-15
IL226450A0 (en)	2013-07-31
EP2651436A1 (en)	2013-10-23
CN103249431B (zh)	2016-11-02
TW201305192A (zh)	2013-02-01
SI2651436T1 (sl)	2016-07-29
US20130287809A1 (en)	2013-10-31
PL2651437T3 (pl)	2016-07-29
MX344706B (es)	2017-01-03
UA110806C2 (uk)	2016-02-25
AU2011343368B2 (en)	2015-08-20
CA2819297A1 (en)	2012-06-21
CN103260642B (zh)	2018-03-16
BR112013014598A2 (pt)	2017-09-19
HUE028452T2 (en)	2016-12-28
KR101951894B1 (ko)	2019-02-26
SG190937A1 (en)	2013-07-31
ME02380B (me)	2016-06-20
US10441648B2 (en)	2019-10-15
EA201390630A1 (ru)	2013-12-30
CN103260642A (zh)	2013-08-21
HRP20160606T1 (hr)	2016-07-01
DK2651436T3 (da)	2016-06-20
HRP20191843T1 (hr)	2019-12-27
CN106822883A (zh)	2017-06-13
ZA201304014B (en)	2017-04-26
SI2651437T1 (sl)	2016-05-31
EP3023106B1 (en)	2019-07-31
US9352030B2 (en)	2016-05-31
EP3023106A1 (en)	2016-05-25
US20190183998A1 (en)	2019-06-20
ES2574403T3 (es)	2016-06-17
SG190731A1 (en)	2013-07-31
ZA201304015B (en)	2018-12-19
EP2651437A1 (en)	2013-10-23
IL226448A (en)	2017-09-28
BR112013014599A2 (pt)	2016-09-27
MY161412A (en)	2017-04-14
CO6751287A2 (es)	2013-09-16
SI3023106T1 (sl)	2019-11-29

Publication	Publication Date	Title
ZA201304014B (en)	2017-04-26	Mycobacterium antigenic composition
GB201003924D0 (en)	2010-04-21	Immunogenic composition
GB201002983D0 (en)	2010-04-07	Nutritinal composition
GB201006200D0 (en)	2010-06-02	Composition
GB201015132D0 (en)	2010-10-27	Vaccine composition
ZA201208093B (en)	2013-06-26	Mycobacterial antigen composition
GB201006178D0 (en)	2010-06-02	Composition
GB201021269D0 (en)	2011-01-26	Composition
GB201017048D0 (en)	2010-11-24	Composition
GB201019988D0 (en)	2011-01-05	Composition
GB201005927D0 (en)	2010-05-26	Improved composition
GB201007531D0 (en)	2010-06-23	Composition
GB201006214D0 (en)	2010-06-02	Composition
GB201006204D0 (en)	2010-06-02	Composition
GB201004717D0 (en)	2010-05-05	Composition
GB201014967D0 (en)	2010-10-20	Composition
GB201010657D0 (en)	2010-08-11	Composition
PL2534235T3 (pl)	2014-03-31	Kompozycja
GB201018130D0 (en)	2010-12-08	Composition
GB201006182D0 (en)	2010-06-02	Composition
GB201006012D0 (en)	2010-05-26	Composition
HK1190619A (en)	2014-07-11	Mycobacterium antigenic composition
HK1190618A (en)	2014-07-11	Mycobacterium antigenic composition
GB201003918D0 (en)	2010-04-21	Immunogenic composition
GB201006369D0 (en)	2010-06-02	Polysiloxane composition